FIGURE 4: Mean change from baseline in iPTH concentration during treatment and 60 days after treatment withdrawal. Data are shown as the mean change ±

Slides:

Advertisements

Similar presentations

Fig. 4. Carer ratings of executive functioning (Dysexecutive Questionnaire) and memory (Memory Checklist) in the 3 groups at the beginning and end of the.

Advertisements

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Fig. 1. Significant clusters in the amygdala and dlPFC, four-way interaction effect (group by valence by temperature by time), small volume corrected.

From: Dynamic De/Centralization in Canada, 1867–2010

Figure 3: (a and b) Preoperative contrast-eCT

Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.

J Exp Bot. 2017;68(17): doi: /jxb/erx352

Figure 2. Chronic kidney disease risk tool application.

Fig. 1. Scheme for classifying renal function without access to laboratory test results. *Renal-specific drugs: phosphate binders (ATC codes.

Fig 1 The CONSORT participant flow diagram for primary endpoints.

From: Rethinking the Effects of Financial Globalization *

Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.

From: Learning by Working in Big Cities

From: THE FALLACIES OF PATENT-HOLDUP THEORY

Fig. 1. Trial structure for the experimental task.

Fig. 1 Nodes in a conceptual knowledge graph

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

From: Nutrition and brain development in early life

From: Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level.

From: Detection of Bacteriuria by Canine Olfaction

Fig. 1. Age-dependent distribution of AKI risk factors

Figure 1: (A, frontal) and (B, lateral) Final result, 4 months post-operative, after right breast reconstruction using combined TRAM flap and LDMF. From:

Figure 2. Temperature-entropy diagram and the flow resistances of the power plant model of Figure 1. From: Thermodynamic optimization of a triple-shaft.

From: Introducing the PRIDE Archive RESTful web services

Fig. 1 No. 17 Trinidad trap baited with hamster in swamp forest in Tennessee. (Online figure in color.) From: Use of Hamster-Baited No. 17 Trinidad Mosquito.

Fig. 1. RUbioSeq pipelines for exome variant detection and BS-Seq analyses. Dark gray boxes correspond to the main steps of the pipelines. Light gray boxes.

Figure 3: Full-body skeletal scintigraphy.

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Source:Zimnisky (2014). From: An Autopsy of Cooperation: Diamond Dealers and the Limits of Trust-Based Exchange Journal of Legal Analysis. Published online.

Figure 1. Study population diagram

Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

ADAb: anti-drug antibody.

FIGURE 1 Kidney biopsies of Patients 1 and 2

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Flow chart of patient enrollment and exclusion

Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.

Fig. 1 Mean change from baseline in ANC ± s. e

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).

Graph 1. The number of homicide cases per year discussing neuro-evidence. Unless provided in the caption above, the following copyright applies to the.

Figure 1. Analysis of human TRIM5α protein with Blast-Search and PhyML+SMS ‘One click’ workflow. (A) NGPhylogeny.fr ... Figure 1. Analysis of human TRIM5α.

Figure 2. Natural history of chlamydia transmission, with arrows showing the transitions between health states. Figure 2. Natural history of chlamydia.

Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.

FIGURE 1 Study consort diagram

Fig. 2 Case 2. Levels of serum creatinine and anti-GBM antibodies before and during treatment with cyclophosphamide, ... Fig. 2 Case 2. Levels of serum.

Figure 1. Illustration of DGR systems and their prediction using myDGR

FIGURE 1 Food groups consumed (mean, g/d) among US infants and young children by age group and tertile of mean ... FIGURE 1 Food groups consumed (mean,

Figure 1 Study flowchart and patient flow

Figure 1. Schematic diagram of solar energy and coal-fired power generation system. Unless provided in the caption above, the following copyright applies.

Figure 1. Uncertainty reduction, value creation, and appropriation in two case studies. Unless provided in the caption above, the following copyright applies.

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability.

Figure 1. MERMAID web server interface (Start page, Parameter page): MERMAID provides two ways to submit a protein ... Figure 1. MERMAID web server interface.

Figure 1. The framework of NetGO with seven steps

Figure 1 Patient disposition

Figure 1. Trial profile. (A) Part A and (B) part B

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Figure 1 Genetic results. No case had more than one diagnostic result

Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph ... Figure 1. (A) Baseline contrast-enhanced.

Figure 1. Prevalence of parasitic infection and anemia among the children. Unless provided in the caption above, the following copyright applies to the.

Source:Zimnisky (2014). Source:Zimnisky (2014).

Figure 1 Mechanisms of mitral regurgitation.

Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.

Presentation transcript:

FIGURE 4: Mean change from baseline in iPTH concentration during treatment and 60 days after treatment withdrawal. Data are shown as the mean change ± standard deviation. BL, baseline; iPTH, intact parathyroid hormone. From: Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study Nephrol Dial Transplant. 2013;28(9):2260-2268. doi:10.1093/ndt/gft227 Nephrol Dial Transplant | © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

FIGURE 3: Mean change from baseline in serum calcium concentration during treatment and 60 days after treatment withdrawal. Data are shown as the mean change ± standard deviation. BL,baseline. From: Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study Nephrol Dial Transplant. 2013;28(9):2260-2268. doi:10.1093/ndt/gft227 Nephrol Dial Transplant | © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

FIGURE 2: Mean change from baseline in serum phosphateconcentration during treatment and 60 days after treatmentwithdrawal. Data are shown as the mean change ± standard deviation. BL, baseline. From: Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study Nephrol Dial Transplant. 2013;28(9):2260-2268. doi:10.1093/ndt/gft227 Nephrol Dial Transplant | © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

FIGURE 1: Mean change from baseline in (A) serum phosphorus, (B) calcium and (C) iPTH concentrations to last on-treatment measurement and 60 days after treatment withdrawal. iPTH, intact parathyroid hormone; LS, least squares. <sup>a</sup>P < 0.001 versus placebo. <sup>b</sup>P = 0.001 versus placebo. <sup>c</sup>P < 0.05 versus placebo. From: Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study Nephrol Dial Transplant. 2013;28(9):2260-2268. doi:10.1093/ndt/gft227 Nephrol Dial Transplant | © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

FIGURE 5: Mean percentage change from baseline in BAP concentration to (A) last on-treatment measurement and (B) 60 days after treatment withdrawal, by baseline iPTH. BAP, bone-specific alkaline phosphatase; iPTH, intact parathyroid hormone. <sup>a</sup>P ≤ 0.001 versus placebo. <sup>b</sup>P < 0.05 versus placebo. From: Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study Nephrol Dial Transplant. 2013;28(9):2260-2268. doi:10.1093/ndt/gft227 Nephrol Dial Transplant | © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

FIGURE 6: Scatter plots of the change from baseline in BAPconcentration versus change from baseline in iPTH concentration,by baseline iPTH concentration. Changes from baseline to last on-treatment values for iPTH and BAP are shown for (A) all subjects, (B) subjects with iPTH concentration <70 pg/mL and (C) subjects with iPTH concentration ≥70 pg/mL. BAP, bone-specific alkaline phosphatase; iPTH, intact parathyroid hormone. From: Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study Nephrol Dial Transplant. 2013;28(9):2260-2268. doi:10.1093/ndt/gft227 Nephrol Dial Transplant | © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com